Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.
Saint-Joseph University
1,000 participants
Nov 9, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults. The main questions it aims to answer are: * Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol? * How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure) * Are respiratory events more common in a certain group? * Is the surgeon's satisfaction similar among groups? * Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group? Researchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols. Participants will : * Receive one of these three protocols * Be operated for one or both eyes * Monitored during the whole surgery and in the recovery room * Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.
Eligibility
Inclusion Criteria1
- Adults undergoing cataract surgery
Exclusion Criteria3
- Severe hepatic insufficiency
- Third degree AV block
- Patient refusal
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine (loading dose 0.5 µg/kg over 10 minutes, followed by maintenance at 0.25µg/kg/h).
Propofol (target-controlled infusion to achieve a Ramsay Sedation Score of 2-3 as much as possible).
Single fentanyl bolus (1 µg/kg).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07556133